Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorMANIRAKIZA, Alexandre
dc.contributor.authorTONDEUR, Laura
dc.contributor.authorYVETTE BATOUMBOU KETTA, Marie
dc.contributor.authorSEPOU, Abdoulaye
dc.contributor.authorSERDOUMA, Eugene
dc.contributor.authorGONDJE, Samuel
dc.contributor.authorGERAUD BANTHAS BATA, Ghislain
dc.contributor.authorBOULAY, Aude
dc.contributor.authorMETHODE MOYEN, Jean
dc.contributor.authorSAKANGA, Olga
dc.contributor.authorLE-FOULER, Lenaig
dc.contributor.authorKAZANJI, Mirdad
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBRIAND, Valerie
dc.contributor.authorPIERRE LOMBART, Jean
dc.contributor.authorVRAY, Muriel
dc.date.accessioned2021-10-11T10:08:47Z
dc.date.available2021-10-11T10:08:47Z
dc.date.issued2021-08-18
dc.identifier.issn1360-2276en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112717
dc.description.abstractEnOBJECTIVE: The main objective of the MACOMBA (Maternity and Control of Malaria-HIV co-infection in Bangui) trial was to show that cotrimoxazole (CTX) is more effective than Sulphadoxine-Pyremethamine-IPTp (IPTp-SP) to prevent placental malaria infection (primary endpoint) among HIV-positive pregnant women with a CD4+ count ≥350 cells/mm(3) in Bangui, CAR. METHODS: MACOMBA is a multicenter, open-label randomized trial conducted in four maternity hospitals in Bangui. Between 2013 and 2017, 193 women were randomized and 112 (59 and 53 in CTX and IPTp-SP arms, respectively) were assessed for placental infection defined by microscopic parasitemia or PCR. RESULTS: Thirteen women had a placental infection: 5 in the CTX arm (1 by microscopic placental parasitemia and 4 by PCR) and 8 by PCR in the SP-IPTp (8.5% vs 15.1%, p = 0.28). The percentage of newborns with low birthweight (< 2500 g) did not differ statistically between the two arms. Self-reported compliance to CTX prophylaxis was good. There was a low overall rate of adverse events in both arms. CONCLUSION: Although our results do not allow us to conclude that CTX is more effective, drug safety and good compliance among women with this treatment favour its widespread use among HIV-infected pregnant women, as currently recommended by WHO.
dc.language.isoENen_US
dc.subject.enMalaria
dc.subject.enPregnant women
dc.subject.enProphylaxis HIV
dc.title.enCotrimoxazole versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in HIV-infected pregnant women in Bangui, Central African Republic: a Pragmatic Randomized Controlled Trial
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/tmi.13668en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34407273en_US
bordeaux.journalTropical Medicine and International Healthen_US
bordeaux.page1314-1323en_US
bordeaux.volume26en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue10en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamIDLICen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03373065
hal.version1
hal.date.transferred2021-10-11T10:08:51Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Tropical%20Medicine%20and%20International%20Health&amp;rft.date=2021-08-18&amp;rft.volume=26&amp;rft.issue=10&amp;rft.spage=1314-1323&amp;rft.epage=1314-1323&amp;rft.eissn=1360-2276&amp;rft.issn=1360-2276&amp;rft.au=MANIRAKIZA,%20Alexandre&amp;TONDEUR,%20Laura&amp;YVETTE%20BATOUMBOU%20KETTA,%20Marie&amp;SEPOU,%20Abdoulaye&amp;SERDOUMA,%20Eugene&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée